Cholangiocarcinoma News

Tibsovo First Targeted Therapy FDA Approved for Advanced or Metastatic CCA with IDH1 Mutation

September/October 2021, Vol 2, No 3

On August 25, 2021, the FDA approved ivosidenib (Tibsovo; Servier Pharmaceuticals), an oral IDH1 inhibitor, for the treatment of adults with previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) and an IDH1 mutation, as detected by an FDA-approved test. The FDA granted ivosidenib a priority review for this indication and an orphan drug designation.

On the same day, the FDA also approved the Oncomine Dx Target Test, as a companion diagnostic test for selecting patients with CCA whose disease harbors the IDH1 mutation to receive treatment with ivosidenib.

Ivosidenib was previously approved by the FDA for the treatment of patients with relapsed or refractory acute myeloid leukemia (AML) and IDH1 mutation, as detected by an FDA-approved test, and for patients with newly diagnosed AML and IDH1 mutation who are aged ≥75 years or who have comorbidities that preclude the use of intensive induction chemotherapy.

Up to 20% of patients with CCA have IDH1 mutation, which is associated with poor prognosis.

“Patients living with IDH1-mutated cholangiocarcinoma, especially those whose disease progresses following chemotherapy, are in urgent need of new treatment options,” said Rachna T. Shroff, MD, MS, Associate Professor of Medicine, University of Arizona, and Chief of GI Medical Oncology at the University of Arizona Cancer Center, Tucson. “In addition to an acceptable safety profile, Tibsovo demonstrated an impressive, significant benefit in progression-free survival, underscoring its importance as a new option for patients battling this aggressive cancer,” Dr Shroff added.

The FDA approval was based on results from the ClarIDHy clinical trial, a phase 3, multicenter, randomized, double-blind, placebo-controlled study. This study included 185 adults with locally advanced or metastatic CCA and an IDH1 mutation who had previously received up to 2 treatment regimens, including at least 1 gemcitabine- or 5-fluorouracil–containing regimens. The 185 patients in the ClarIDHy study received 500 mg oral ivosidenib or placebo once daily, until disease progression or until unacceptable adverse events.

The primary end point was progression-free survival (PFS), as determined by an independent review committee. The results showed a significant improvement in PFS in patients who received ivosidenib versus placebo (95% confidence interval [CI], 0.25-0.54; P <.0001). The difference in overall survival was not significant (95% CI, 0.56-1.12; P = .093).

At a 6-month follow-up, 32% of patients who received ivosidenib remained free of disease progression; by 12 months of follow-up, this rate was 22%.

The study design allowed patients to cross over from the placebo arm to the ivosidenib arm at disease progression. A majority (70%) of the patients in the placebo arm crossed over to the ivosidenib arm after radiographic disease progression.

The most common (≥15%) adverse reactions reported with ivosidenib were fatigue, nausea, abdominal pain, diarrhea, cough, decreased appetite, ascites, vomiting, anemia, and rash.

“Before today’s approval of Tibsovo, there were no approved targeted therapies available to cholangiocarcinoma patients harboring the IDH1 mutation, and limited chemotherapy options available to patients with advanced disease,” said Stacie Lindsey, Founder and CEO, the Cholangiocarcinoma Foundation. “This approval brings new hope to the cholangiocarcinoma community, and we are excited that this much-needed new therapeutic option is being made available to patients,” she emphasized.

The recommended dose of oral ivosidenib is 500 mg once daily, taken with or without food, until disease progression or until unacceptable adverse events.

Related Items

Cross-Comparison of Clinical Trials Assessing Futibatinib and Pemigatinib versus Chemotherapy in Patients with CCA and FGFR2 Fusion or Other Rearrangements
2022 Year in Review: Cholangiocarcinoma
A comparison of clinical trials found progression-free survival with futibatinib to be significantly greater compared with chemotherapy and that trials favor futibatinib over pemigatinib for all efficacy parameters.
Utility of Liquid Biopsy for Identification of Molecular Alterations in Solid Tumors
2022 Year in Review: Cholangiocarcinoma
Real-world evidence supports a role for liquid biopsy in identifying molecular alterations and offering personalized treatment options, with IDH1 identified in a patient with cholangiocarcinoma.
Preliminary Analyses of QOL Data from the ABC-06 Clinical Trial
2022 Year in Review: Cholangiocarcinoma
Preliminary quality-of-life data suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.
NALIRICC Study of Nanoliposomal Irinotecan Combination Therapy in Metastatic BTC
2022 Year in Review: Cholangiocarcinoma
The NALIRICC study did not meet overall survival or progression-free survival end points, with nanoliposomal irinotecan plus 5-fluorouracil falling short in patients with metastatic biliary tract cancer.
Tislelizumab plus GemOx and Lenvatinib as a Conversion Therapy Regimen for Potentially Resectable BTCs
2022 Year in Review: Cholangiocarcinoma
The combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin was shown to be promising as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer in this phase 2 study.
Health-Related QOL Study in Patients with CCA
2022 Year in Review: Cholangiocarcinoma
Study revealed increased financial toxicities in patients with cholangiocarcinoma enrolled in clinical trials and receiving targeted therapies.
Updated Analysis of the LUC2001 Study
2022 Year in Review: Cholangiocarcinoma
Erdafitinib was found to be associated with durable efficacy and manageable toxicity in Asian patients with advanced cholangiocarcinoma with FGFR alterations.
Biliary Tract Cancers: Is Laparoscopic Liver Resection Adequate?
2022 Year in Review: Cholangiocarcinoma
Study finds laparoscopic liver resection was associated with less blood loss and shorter length of stay compared with open liver resection.
The Future of Neoadjuvant Chemotherapy for iCCA
2022 Year in Review: Cholangiocarcinoma
Study found lower rates of margin-positive resection of intrahepatic cholangiocarcinoma with neoadjuvant chemotherapy.
Mayo Clinic Study Assessed Impact of Neoadjuvant Chemoradiation in Patients with Unresectable Perihilar CCA
2022 Year in Review: Cholangiocarcinoma
Neoadjuvant chemoradiation was found to elicit no differences in survival among patients with unresectable perihilar cholangiocarcinoma.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: